Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › PA › Pittsburgh › NPI 1619040284
Lab

Quest Diagnostics Venture LLC

Quest Diagnostics Venture LLC was paid $96.03M by Medicaid between Jan 2018 and Dec 2024, across 329 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 27% of everything it billed.

33Billing provider infoQUEST DIAGNOSTICS VENTURE LLC
PITTSBURGH, PA 15220
33aNPI1619040284assigned 11/15/2006
33bProvider typeClinical Medical Laboratory
28Total paid$96.03M
24GClaims3,644,771
24DCodes billed329
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Pennsylvania

Rank by total paid#2 of 95
Median peer was paid$153K
This provider vs. median629×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$1.0M$2.0M$3.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201825,503$511K
201915,273$303K
2020138,328$3.72M
2021829,259$25.73M
2022838,454$24.64M
2023953,985$24.56M
2024incomplete843,969$16.56M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 27% 432,781 342,423 $26.24M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 24% 372,223 295,460 $23.37M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 6.4% 81,636 69,188 $6.15M
80050 General health panel 2.5% 58,568 58,046 $2.41M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 2.4% 96,751 92,775 $2.31M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 2.3% 94,756 90,773 $2.22M
80053 Comprehensive metabolic panel 1.7% 156,299 143,409 $1.60M
80061 Lipid panel 1.6% 136,439 133,553 $1.57M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 1.5% 45,240 44,283 $1.42M
84443 Thyroid stimulating hormone (TSH) 1.4% 68,438 66,549 $1.34M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 1.3% 50,593 49,151 $1.23M
86480 1.2% 20,794 20,073 $1.20M
317 more codes
87902 1.0% 5,103 $966K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 44,363 $958K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 22,273 $857K
86803 <1% 50,837 $838K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 27,759 $756K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 138,762 $738K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 20,973 $626K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 17,136 $583K
87086 Culture, bacterial; quantitative colony count, urine <1% 70,482 $532K
83036 Hemoglobin; glycosylated (A1C) <1% 90,663 $492K
83655 <1% 49,696 $476K
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel <1% 1,077 $469K
82728 <1% 39,797 $439K
84403 <1% 18,095 $433K
87081 <1% 75,626 $413K
82607 <1% 40,744 $410K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 3,843 $405K
80081 <1% 4,988 $388K
87522 Neg quan hep c or qual rna <1% 12,263 $371K
87088 <1% 47,384 $366K
86003 <1% 3,165 $362K
87340 <1% 28,727 $355K
87536 <1% 3,670 $352K
81596 <1% 7,152 $344K
84439 <1% 43,486 $311K
80048 Basic metabolic panel (calcium, ionized) <1% 38,611 $302K
83540 <1% 38,386 $294K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 7,344 $270K
86704 <1% 20,786 $270K
84146 <1% 10,538 $229K
84153 <1% 11,165 $225K
85027 <1% 34,267 $223K
86708 <1% 16,808 $222K
86706 <1% 18,997 $216K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 3,571 $215K
86592 <1% 55,104 $190K
87480 <1% 8,308 $188K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 432 $181K
87660 <1% 8,297 $175K
82570 <1% 27,843 $174K
88185 <1% 497 $173K
82784 <1% 8,525 $172K
83550 <1% 37,041 $172K
87186 <1% 21,982 $171K
82670 <1% 8,709 $169K
80076 <1% 20,875 $168K
82043 <1% 23,464 $167K
83970 <1% 4,398 $162K
84402 <1% 6,426 $161K
83735 <1% 25,368 $159K
82746 <1% 19,616 $153K
82248 <1% 26,244 $151K
86235 <1% 2,457 $143K
87077 <1% 20,360 $139K
81001 <1% 54,143 $138K
86618 <1% 6,540 $134K
80074 <1% 2,643 $124K
86038 <1% 8,641 $120K
83001 <1% 6,828 $114K
87070 <1% 15,380 $110K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 3,030 $105K
86317 <1% 5,113 $97K
88142 <1% 5,783 $96K
82565 <1% 16,937 $93K
87510 <1% 5,755 $92K
84702 <1% 5,947 $91K
85610 <1% 25,414 $88K
86780 <1% 6,834 $88K
87150 <1% 2,220 $86K
84703 <1% 9,879 $85K
86665 <1% 1,994 $82K
83002 <1% 4,929 $80K
84481 <1% 3,766 $77K
86334 <1% 2,812 $71K
83615 <1% 10,889 $68K
86361 <1% 2,546 $67K
86160 <1% 2,247 $65K
82627 <1% 3,071 $62K
86787 <1% 3,345 $60K
86617 <1% 1,785 $58K
81513 <1% 4,017 $57K
84520 <1% 12,525 $57K
80197 <1% 4,620 $57K
83880 <1% 1,854 $56K
84100 <1% 9,755 $55K
86800 <1% 3,325 $54K
86300 <1% 2,092 $53K
82977 <1% 6,413 $52K
85652 <1% 18,717 $52K
84165 <1% 3,852 $51K
82652 <1% 1,416 $51K
86147 <1% 597 $50K
86762 <1% 2,594 $49K
86140 <1% 16,666 $47K
84460 <1% 7,355 $46K
87147 <1% 13,023 $44K
82950 <1% 6,717 $42K
88189 <1% 515 $41K
80164 <1% 2,762 $41K
87209 <1% 1,955 $41K
85730 <1% 6,078 $41K
82105 <1% 2,258 $41K
86200 <1% 2,903 $40K
86360 <1% 711 $40K
82024 <1% 1,055 $40K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 1,029 $40K
88112 <1% 533 $40K
84450 <1% 6,297 $39K
82533 <1% 3,324 $39K
84681 <1% 1,461 $38K
86431 <1% 5,199 $38K
82785 <1% 2,291 $38K
84550 <1% 6,885 $38K
86146 <1% 552 $37K
84270 <1% 1,587 $37K
86664 <1% 1,908 $36K
86376 <1% 4,608 $36K
83921 <1% 2,133 $35K
36415 Collection of venous blood by venipuncture <1% 28,657 $35K
87481 <1% 973 $34K
82550 <1% 5,228 $34K
82378 <1% 2,243 $34K
P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge <1% 17,898 $34K
86039 <1% 2,425 $33K
86225 <1% 2,403 $33K
87255 <1% 906 $33K
80069 <1% 4,239 $33K
81511 <1% 365 $33K
88141 <1% 4,365 $31K
83525 <1% 2,825 $30K
83498 <1% 1,477 $29K
87799 <1% 495 $29K
84480 <1% 4,473 $28K
87631 <1% 244 $28K
86359 <1% 627 $28K
84144 <1% 1,716 $28K
83521 <1% 1,261 $27K
84207 <1% 728 $27K
81329 <1% 253 $25K
84436 <1% 7,067 $24K
86705 <1% 2,053 $23K
84134 <1% 1,386 $23K
80178 <1% 3,165 $22K
86357 <1% 592 $22K
84425 <1% 3,237 $22K
86355 <1% 582 $22K
82947 <1% 6,124 $22K
86765 <1% 1,839 $21K
86696 <1% 1,454 $21K
83020 <1% 2,050 $21K
86707 <1% 1,931 $21K
84156 <1% 5,415 $20K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 201 $20K
84305 <1% 829 $20K
85018 <1% 6,635 $20K
88184 <1% 565 $19K
86255 <1% 749 $19K
86008 <1% 216 $18K
80051 <1% 2,890 $18K
82157 <1% 740 $18K
87497 <1% 414 $18K
83993 <1% 814 $17K
86304 <1% 811 $17K
82672 <1% 1,223 $17K
82951 <1% 1,397 $17K
83690 <1% 4,162 $17K
80159 <1% 929 $16K
87177 <1% 1,954 $16K
83721 <1% 1,722 $16K
86850 <1% 1,959 $15K
84630 <1% 1,270 $15K
87205 <1% 3,493 $15K
85045 <1% 3,633 $15K
85246 <1% 507 $15K
82542 <1% 786 $15K
87350 <1% 1,974 $15K
82310 <1% 2,416 $14K
84479 <1% 4,447 $14K
87075 <1% 1,469 $14K
87427 <1% 1,153 $14K
87563 <1% 522 $13K
84466 <1% 920 $13K
88342 <1% 179 $13K
86593 <1% 2,450 $13K
84154 <1% 911 $13K
87512 <1% 511 $12K
85245 <1% 430 $12K
86769 <1% 874 $12K
80359 <1% 147 $12K
82232 <1% 699 $12K
83013 <1% 214 $12K
84445 <1% 591 $12K
86364 <1% 528 $12K
84155 <1% 2,793 $11K
87329 <1% 936 $11K
87045 <1% 1,592 $11K
82530 <1% 407 $11K
86695 <1% 1,307 $11K
80175 <1% 813 $11K
82247 <1% 1,818 $10K
85014 <1% 3,535 $10K
84432 <1% 500 $10K
87800 <1% 429 $10K
87102 <1% 1,040 $10K
84075 <1% 1,809 $10K
88304 <1% 624 $9K
87517 <1% 236 $9K
87625 <1% 259 $9K
84478 <1% 1,508 $9K
82274 <1% 2,882 $9K
86141 <1% 881 $9K
86901 <1% 2,202 $9K
85379 <1% 857 $9K
86900 <1% 2,203 $8K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 95 $8K
80177 <1% 698 $8K
84166 <1% 440 $8K
82040 <1% 2,612 $8K
81270 <1% 83 $8K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 81 $8K
83516 <1% 445 $8K
82525 <1% 672 $7K
81025 <1% 1,790 $7K
85240 <1% 536 $7K
80348 <1% 194 $7K
82150 <1% 1,822 $7K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 72 $6K
84295 <1% 1,184 $6K
86308 <1% 920 $6K
86812 <1% 493 $6K
87101 <1% 641 $6K
82465 <1% 1,163 $6K
81015 <1% 2,208 $6K
86301 <1% 288 $6K
82330 <1% 726 $6K
84482 <1% 481 $5K
83090 <1% 682 $5K
83010 <1% 461 $5K
85613 <1% 426 $5K
80362 <1% 135 $5K
87106 <1% 507 $5K
85004 <1% 697 $5K
82140 <1% 943 $4K
85041 <1% 1,246 $4K
86021 <1% 862 $4K
81003 <1% 1,647 $4K
86702 <1% 320 $4K
87634 <1% 59 $4K
82390 <1% 413 $4K
82952 <1% 1,204 $4K
84140 <1% 138 $4K
86701 <1% 320 $4K
83930 <1% 1,199 $3K
86335 <1% 116 $3K
86709 <1% 231 $3K
80299 <1% 237 $3K
82747 <1% 209 $3K
86644 <1% 176 $3K
82668 <1% 220 $3K
84132 <1% 581 $3K
85048 <1% 908 $3K
86036 <1% 313 $3K
83021 <1% 140 $3K
80055 <1% 223 $3K
85660 <1% 943 $3K
82103 <1% 155 $2K
80156 <1% 127 $2K
84590 <1% 163 $2K
83695 <1% 162 $2K
86341 <1% 40 $2K
82435 <1% 433 $2K
82088 <1% 78 $2K
86682 <1% 63 $2K
82374 <1% 377 $2K
80438 <1% 75 $2K
80183 <1% 138 $2K
85007 <1% 386 $2K
82626 <1% 73 $2K
82085 <1% 160 $1K
81241 <1% 24 $1K
81240 <1% 24 $1K
87076 <1% 111 $1K
86015 <1% 116 $1K
87046 <1% 317 $1K
88300 <1% 170 $979.23
82164 <1% 50 $956.07
84446 <1% 105 $937.19
86777 <1% 42 $724.14
85049 <1% 258 $721.35
83527 <1% 43 $701.81
83520 <1% 81 $677.97
99001 <1% 347 $627.30
88307 <1% 12 $568.72
84244 <1% 41 $502.81
86666 <1% 12 $498.14
85247 <1% 15 $477.50
83835 <1% 37 $450.06
82955 <1% 39 $309.04
86645 <1% 14 $308.62
87807 <1% 24 $297.88
86880 <1% 40 $272.29
87449 <1% 58 $270.96
82985 <1% 16 $262.43
82610 <1% 17 $242.10
82653 <1% 14 $226.10
88311 <1% 13 $114.55
87220 <1% 30 $111.52
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 16 $100.00
84300 <1% 14 $95.40
86735 <1% 78 $92.09
86060 <1% 12 $84.70
99199 Unlisted special service, procedure or report <1% 171 $65.63
82180 <1% 13 $58.26
87185 <1% 14 $47.09
87140 <1% 13 $43.89
86870 0% 13 $0.00
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision 0% 12 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTOBIAS, CHRISTINE (CHIEF EXECUTIVE OFFICER)
Parent organizationQUEST DIAGNOSTICS INCORPORATED